Cesare Cozzarini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5749065/publications.pdf Version: 2024-02-01

		71097	82542
122	5,485	41	72
papers	citations	h-index	g-index
123	123	123	4163
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N+ Patients Treated with Radical Prostatectomy, Extended Pelvic Lymph Node Dissection and Adjuvant Therapy. European Urology, 2009, 55, 261-270.	1.9	263
2	Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 301-309.	6.4	258
3	Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 3939-3947.	1.6	246
4	Functional Outcomes and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2012, 61, 112-127.	1.9	224
5	Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiotherapy and Oncology, 2002, 64, 1-12.	0.6	180
6	Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2–4 pN+ Prostate Cancer: Results of a Matched Analysis. European Urology, 2011, 59, 832-840.	1.9	180
7	Rectal dose–volume constraints in high-dose radiotherapy of localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2003, 57, 953-962.	0.8	177
8	[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1065-1073.	6.4	171
9	Early Salvage Radiotherapy Following Radical Prostatectomy. European Urology, 2014, 65, 1034-1043.	1.9	171
10	Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy. European Urology, 2009, 55, 1003-1011.	1.9	164
11	Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. European Urology, 2012, 62, 472-487.	1.9	157
12	Prognostic Value of Lymph Node Dissection in Patients with Muscle-Invasive Transitional Cell Carcinoma of the Upper Urinary Tract. European Urology, 2008, 53, 794-802.	1.9	137
13	IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiotherapy and Oncology, 2009, 93, 207-212.	0.6	126
14	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. European Urology, 2014, 66, 479-486.	1.9	121
15	Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6–70.2 Gy). International Journal of Radiation Oncology Biology Physics, 2003, 55, 688-694.	0.8	112
16	Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2013, 63, 998-1008.	1.9	107
17	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology, 2016, 69, 728-733.	1.9	102
18	Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. European Urology, 2012, 61, 443-451.	1.9	101

#	Article	IF	CITATIONS
19	Higher-than-expected Severe (Grade 3–4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients. European Urology, 2014, 66, 1024-1030.	1.9	94
20	Need for High Radiation Dose (≥70 Gy) in Early Postoperative Irradiation After Radical Prostatectomy: A Single-Institution Analysis of 334 High-Risk, Node-Negative Patients. International Journal of Radiation Oncology Biology Physics, 2009, 75, 966-974.	0.8	87
21	Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. European Urology, 2018, 73, 890-896.	1.9	87
22	Predicting Survival of Patients with Node-positive Prostate Cancer Following Multimodal Treatment. European Urology, 2014, 65, 554-562.	1.9	86
23	Significant reduction of acute toxicity following pelvic irradiation with Helical Tomotherapy in patients with localized prostate cancer. Radiotherapy and Oncology, 2007, 84, 164-170.	0.6	84
24	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3NO Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. European Urology, 2017, 71, 886-893.	1.9	77
25	Predicting toxicity in radiotherapy for prostate cancer. Physica Medica, 2016, 32, 521-532.	0.7	75
26	[¹¹ C]Choline Positron Emission Tomography/Computerized Tomography to Restage Prostate Cancer Cases With Biochemical Failure After Radical Prostatectomy and No Disease Evidence on Conventional Imaging. Journal of Urology, 2010, 184, 938-943.	0.4	74
27	Clinical Factors Predicting Late Severe Urinary Toxicity After Postoperative Radiotherapy for Prostate Carcinoma: A Single-Institute Analysis of 742 Patients. International Journal of Radiation Oncology Biology Physics, 2012, 82, 191-199.	0.8	74
28	Evidence of Limited Motion of the Prostate by Carefully Emptying the Rectum as Assessed by Daily MVCT Image Guidance with Helical Tomotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 71, 611-617.	0.8	71
29	Dose–Volume Relationships for Acute Bowel Toxicity in Patients Treated With Pelvic Nodal Irradiation for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 29-35.	0.8	71
30	Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose–volume histograms and normal tissue complication probability. Radiotherapy and Oncology, 2002, 63, 249-255.	0.6	70
31	Dose–volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiotherapy and Oncology, 2016, 118, 79-84.	0.6	68
32	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	1.9	60
33	Phase l–II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 392-398.	0.8	58
34	To Bleed or Not to Bleed. A Prediction Based on Individual Gene Profiling Combined With Dose–Volume Histogram Shapes in Prostate Cancer Patients Undergoing Three-Dimensional Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1431-1440.	0.8	55
35	Target delineation in post-operative radiotherapy of brain gliomas: Interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans. Radiotherapy and Oncology, 2005, 75, 217-223.	0.6	54
36	Helical Tomotherapy vs. Intensity-Modulated Proton Therapy for Whole Pelvis Irradiation in High-Risk Prostate Cancer Patients: Dosimetric, Normal Tissue Complication Probability, and Generalized Equivalent Uniform Dose Analysis. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1589-1600.	0.8	54

#	Article	IF	CITATIONS
37	First application of a pixel-wise analysis on bladder dose–surface maps in prostate cancer radiotherapy. Radiotherapy and Oncology, 2016, 119, 123-128.	0.6	47
38	Relationships between bladder dose–volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. Radiotherapy and Oncology, 2014, 111, 100-105.	0.6	43
39	Toxicity and efficacy of salvage carbon 11â€choline positron emission tomography/computed tomographyâ€guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU International, 2017, 119, 406-413.	2.5	43
40	Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. International Journal of Radiation Oncology Biology Physics, 2004, 59, 674-683.	0.8	42
41	Feasibility of safe ultra-high (EQD ₂ >100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy. Acta Oncológica, 2011, 50, 25-34.	1.8	42
42	Contouring Variability of the Penile Bulb on CT Images: Quantitative Assessment Using a Generalized Concordance Index. International Journal of Radiation Oncology Biology Physics, 2012, 84, 841-846.	0.8	41
43	Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase l–II study. Radiotherapy and Oncology, 2008, 88, 26-33.	0.6	39
44	Survival Following Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiotherapy in Patients With Prostate Cancer: The Impact of Competing Causes of Mortality and Patient Stratification. European Urology, 2013, 64, 557-564.	1.9	39
45	High-Dose Adjuvant Radiotherapy After Radical Prostatectomy With or Without Androgen Deprivation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 960-965.	0.8	38
46	Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: A comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy. Radiotherapy and Oncology, 2009, 93, 57-63.	0.6	37
47	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. European Urology, 2018, 73, 512-518.	1.9	36
48	Physics aspects of prostate tomotherapy: Planning optimization and image-guidance issues. Acta Oncológica, 2008, 47, 1309-1316.	1.8	35
49	Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: A treatment planning comparison. Radiotherapy and Oncology, 2011, 98, 74-80.	0.6	32
50	Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series. International Journal of Radiation Oncology Biology Physics, 2012, 83, 624-629.	0.8	29
51	Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study. Radiotherapy and Oncology, 2015, 116, 185-191.	0.6	29
52	Modelling the Impact of Fractionation on Late Urinary Toxicity After Postprostatectomy Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1250-1257.	0.8	27
53	Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-Pelvis Irradiation With Different Intensity Modulated Radiation Therapy Techniques Is Not Negligible and Is Prolonged: Preliminary Results of a Longitudinal, Observational Study. International Journal of Radiation Oncology Biology Physics. 2016. 95, 690-695.	0.8	26
54	Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose–volume effects. Radiotherapy and Oncology, 2017, 124, 296-301.	0.6	26

#	Article	IF	CITATIONS
55	Elective nodal radiotherapy in prostate cancer. Lancet Oncology, The, 2021, 22, e348-e357.	10.7	26
56	Predictors of acute bowel toxicity in patients treated with IMRT whole pelvis irradiation after prostatectomy. Radiotherapy and Oncology, 2010, 97, 71-75.	0.6	25
57	Salvage therapy of small volume prostate cancer nodal failures: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 24-35.	4.4	25
58	Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. Radiotherapy and Oncology, 2016, 118, 92-98.	0.6	22
59	Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. Lung Cancer, 2004, 44, 231-239.	2.0	21
60	Modeling set-up error by daily MVCT for prostate adjuvant treatment delivered in 20 fractions: Implications for the assessment of the optimal correction strategies. Radiotherapy and Oncology, 2009, 93, 246-252.	0.6	21
61	Anatomical and clinical predictors of acute bowel toxicity in whole pelvis irradiation for prostate cancer with Tomotherapy. Radiotherapy and Oncology, 2011, 101, 460-464.	0.6	21
62	Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the dose–effect. Radiotherapy and Oncology, 2017, 125, 101-106.	0.6	21
63	Remission of Refractory Neurosarcoidosis Treated With Brain Radiotherapy. Neurologist, 2008, 14, 120-124.	0.7	20
64	Gamma Knife Radiosurgery for Treatment of Cerebral Metastases From Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e463-e468.	0.8	20
65	Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward. Tumori, 2017, 103, 395-404.	1.1	20
66	Correlation between surrogates of bladder dosimetry and dose–volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy. Radiotherapy and Oncology, 2012, 105, 180-183.	0.6	18
67	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiotherapy and Oncology, 2013, 109, 211-216.	0.6	18
68	Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning. Radiation Oncology, 2011, 6, 123.	2.7	17
69	A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. Radiotherapy and Oncology, 2007, 82, 30-37.	0.6	16
70	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. International Journal of Radiation Oncology Biology Physics, 2013, 87, 960-967.	0.8	16
71	Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: A treament planning comparison. Radiotherapy and Oncology, 2013, 107, 207-212.	0.6	16
72	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pNO Patients With a Comprehensive Tumor Control Probability Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, 333-340.	0.8	16

#	Article	IF	CITATIONS
73	Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT. Acta Oncológica, 2019, 58, 1757-1764.	1.8	15
74	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. European Urology, 2019, 76, 443-449.	1.9	14
75	Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases. British Journal of Radiology, 2020, 93, 20190353.	2.2	14
76	Impact of the radiotherapy technique on the correlation between dose–volume histograms of the bladder wall defined on MRI imaging and dose–volume/surface histograms in prostate cancer patients. Physics in Medicine and Biology, 2013, 58, N115-N123.	3.0	12
77	Baseline status and dose to the penile bulb predict impotence 1Âyear after radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2016, 192, 297-304.	2.0	10
78	[¹¹ C]choline-PET-guided Helical Tomotherapy and Estramustine in a Patient with Pelvic-Recurrent Prostate Cancer: Local Control and Toxicity Profile after 24 Months. Tumori, 2010, 96, 613-617.	1.1	9
79	Clinical Implementation of Knowledge-Based Automatic Plan Optimization for Helical Tomotherapy. Practical Radiation Oncology, 2021, 11, e236-e244.	2.1	9
80	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 204-209.	1.6	8
81	Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges. Frontiers in Oncology, 2020, 10, 527121.	2.8	8
82	Megavoltage CT Images of Helical Tomotherapy Unit for Radiation Treatment Simulation: Impact on Feasibility of Treatment Planning in a Prostate Cancer Patient with Bilateral Femoral Prostheses. Tumori, 2011, 97, 221-224.	1.1	7
83	Contemporary role of radiation therapy in the adjuvant or salvage setting following radical prostatectomy. Current Opinion in Urology, 2011, 21, 206-210.	1.8	7
84	The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer. Current Oncology Reports, 2015, 17, 53.	4.0	7
85	Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects. Frontiers in Oncology, 2020, 10, 1207.	2.8	7
86	Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer. Cancers, 2021, 13, 4970.	3.7	7
87	Salvage radiotherapy: A plea for dose-escalation with intensity-modulated radiotherapy. European Journal of Cancer, 2012, 48, 1415-1416.	2.8	6
88	Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. Radiotherapy and Oncology, 2021, 158, 74-82.	0.6	5
89	Postoperative Radiotherapy in Prostate Cancer: Acquired Certainties and Still Open Issues. A Review of Recent Literature. Tumori, 2011, 97, 1-8.	1.1	4
90	Radiation Induced Lymphocyte Apoptosis: An Effective Way of "Tailoring―Radiotherapy to the Right Patients Only?. EBioMedicine, 2015, 2, 1852-1853.	6.1	4

#	Article	IF	CITATIONS
91	Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment?. European Urology, 2017, 71, 44-45.	1.9	4
92	Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU International, 2019, 124, 35-39.	2.5	4
93	A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. Clinical Genitourinary Cancer, 2017, 15, e525-e527.	1.9	3
94	A non-invasive ultrasound imaging method to measure acute radiation-induced bladder wall thickening in rats. Radiation Oncology, 2020, 15, 240.	2.7	3
95	Salvage radiation therapy after prostatectomy: Understanding the dose–response effect. Radiotherapy and Oncology, 2017, 123, 486-487.	0.6	2
96	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology Oncology, 2021, 4, 301-304.	5.4	2
97	Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy. Cancers, 2021, 13, 3243.	3.7	2
98	Second Tumor Induction Risk in IMRT for Prostate Cancer. Health Physics, 2015, 109, 549-555.	0.5	1
99	Dose Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to Pay for a Significant Prospective Benefit. Journal of Clinical Oncology, 2016, 34, 1704-1705.	1.6	1
100	The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 962-969.	6.4	1
101	In Regard to Wages et al and Leite et al. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1548-1549.	0.8	1
102	The prognostic significance of capsular incision into tumor during radical prostatectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 549-550.	1.5	1
103	Editorial Comment on: Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer—A New Standard?. European Urology, 2008, 54, 540-541.	1.9	0
104	899 DOES BIOCHEMICAL PROGRESSION AFTER RADICAL PROSTATECTOMY AND ADJUVANT RADIOTHERAPY FOR LOCALLY ADVANCED PROSTATE CANCER INVARIABLY IMPACT CANCER-SPECIFIC MORTALITY?. Journal of Urology, 2011, 185, .	0.4	0
105	1793 AGE AND AGGRESSIVE PROSTATE CANCER IN PATIENTS WITH LOW RISK CHARACTERISTICS. IMPLICATIONS FOR CONSERVATIVE MANAGEMENT. Journal of Urology, 2011, 185, .	0.4	0
106	723 ADJUVANT RADIOTHERAPY REDUCES THE RATE OF URINARY CONTINENCE RECOVERY AFTER RADICAL PROSTATECTOMY IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER PATIENTS. Journal of Urology, 2011, 185, .	0.4	0
107	Low-dose-rate Brachytherapy, Radical Prostatectomy, or External-beam Radiation Therapy for Localised Prostate Carcinoma: The Growing Dilemma. European Urology, 2011, 60, 894-896.	1.9	0
108	In Reply to Yu. International Journal of Radiation Oncology Biology Physics, 2012, 84, 301-302.	0.8	0

#	Article	IF	CITATIONS
109	Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's Letter to the Editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected Severe (Grade 3–4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients. Eur Urol 2014;66:1024–30. European Urology, 2014, 66, e113-e114.	1.9	0
110	Reply to Berardino De Bari, Stefano Arcangeli, and Filippo Alongi's Letter to the Editor re: Nazareno Suardi, Andrea Gallina, Giuliana Lista, et al. Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. Eur Urol 2014;65:546–51. European Urology, 2015, 67, e27-e28. Reply to Salvador Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Dedition Therapy of International Urich risk Prostate Cozzarini. Whole-pelvis Radiotherapy in the	1.9	0
111	Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44–5. Preclinical Combinatory Approach to Enhance Radiotherapy Effects and Reduce its Morbidity may be Tested in the Clinic. European Urology, 2017, 72, e34-e35.	1.9	0
112	Post-prostatectomy Radiotherapy: Does "Salvage―Really Equal "Adjuvant�. European Urology, 2017, 72 710-711.	<u>)</u> 1.9	0
113	PD08-05â€∫DEVELOPMENT AND VALIDATION OF A NOVEL NOMOGRAM PREDICTING LONG-TERM PROGRESSION IN PATIENTS TREATED WITH EARLY SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY: THE KEY ROLE OF PSA KINETICS. Journal of Urology, 2021, 206, .	0.4	0
114	PD15-04 THERE IS NO WAY TO COMPENSATE FOR A NON-TIMELY USE OF SALVAGE RADIATION THERAPY IN MEN WITH RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2019, 201,	0.4	0
115	MP22-01 WHAT IS THE BEST DEFINITION OF BIOCHEMICAL RESPONSE TO SALVAGE RADIATION THERAPY IN PROSTATE CANCER PATIENTS TREATED FOR PSA RISING AFTER RADICAL PROSTATECTOMY? RESULTS FROM A MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2019, 201, .	0.4	0
116	PD15-05 WHAT IS THE RISK OF LATE RECURRENCE AND MORTALITY AFTER SALVAGE RADIATION THERAPY FO POST-PROSTATECTOMY PSA RISING? A LONG-TERM, MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2019, 201, .	₹ 0.4	0
117	MP22-20 ASSESSING THE IMPACT AND PREDICTORS OF OTHER-CAUSE MORTALITY IN PATIENTS TREATED WIT POST-PROSTATECTOMY SALVAGE RADIATION THERAPY IN ORDER TO AVOID POSSIBLE OVERTREATMENT: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL STUDY. Journal of Urology, 2019, 201, .	H 0.4	0
118	MP79-20 ASSESSING THE OPTIMAL TIMING OF POSTOPERATIVE TREATMENTS AFTER RADICAL PROSTATECTOM IN PATIENTS WITH NODE-POSITIVE PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2020, 203, .	ИҮ 0.4	0
119	MP37-16 ASSESSING THE IMPACT OF SALVAGE RADIATION THERAPY FIELD AFTER RADICAL PROSTATECTOMY: LONG-TERM ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2020, 203, .	A 0.4	0
120	MP37-11 ASSOCIATION BETWEEN THE EXTENT OF LYMPH NODE DISSECTION AND SEVERE TOXICITY IN MEN WITH PROSTATE CANCER TREATED WITH POST-PROSTATECTOMY RADIATION THERAPY: RESULTS FROM A LARGE MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2020, 203, .	0.4	0
121	MP37-17 CHANGING PATTERNS AND PREDICTORS OF SALVAGE RADIATION THERAPY USE OVER TIME IN PATIENTS TREATED FOR POST-PROSTATECTOMY BIOCHEMICAL RECURRENCE: A TREND ANALYSIS OVER A 20-YEAR PERIOD FROM A MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2020, 203, .	0.4	0
122	822â€Local radiotherapy synergizes with tumor-specific TCR redirected T cells in the rejection of prostate cancer. , 2020, , .		0